One-shot flu vaccine in the offing

Bs_logoImage
Press Trust of India Melbourne
Last Updated : Jun 05 2017 | 5:57 PM IST
Scientists have discovered flu- fighting white blood cells in our noses that can stop the virus from reaching the lungs, a finding that may pave the way for a one-shot vaccine against various types of infuenza.
Researchers from University of Melbourne in Australia started by looking at a particular white blood cell - the resident memory CD8 T cells or Trms.
Located in the lungs, the Trms are excellent at protecting against different strains of flu, researchers said.
The flu vaccine most people get each year works by stimulating white blood cells to produce the antibodies to fight a specific infection, researchers said.
However, resident memory T cells, take up residence in and around organs, rather than living a roving life in the bloodstream, they said.
"We had identified a cell type that could provide great protection against different strains of influenza virus, but because they decayed so rapidly we would still have to constantly vaccinate the population," said Angela Pizzolla, research fellow at University of Melbourne.
Researchers then found a population of Trms living in nasal tissue that and unlike their counterparts in the lung, they can live for a very long time.
They tracked these cells in lung and nasal tissue and found that while a population of lung Trms cells would drop at rate of 100,000 cells down to just 1000 cells over a period of 100 days, the Trms cell population in the nasal tissue remained stable.
This meant that the flu-fighting cells in the nasal tissue can potentially disable the inhaled influenza virus in the nose and upper airways, preventing the infection from reaching the lungs, researchers said.
It also means scientists could look at developing a vaccine that stimulates these Trms in the nose, halting specific strains of virus before it even enters the respiratory system, they said.
"We basically stopped influenza at the gates," said Linda Wakim from University of Melbourne.
The influenza virus is notoriously difficult to treat and manage. It is highly contagious - meaning it is very good at spreading from person to person.
This is a big problem for influenza vaccine development. Our current flu vaccines work by training the body to recognise a component on the surface on an influenza virus particle, researchers said.
"Instead of recognising external parts of the virus, which are constantly changing, these cells are trained to recognise internal parts of the virus. These parts of the virus are equivalent to our internal organs," Wakim said.
It means a vaccine that induces flu fighting Trm cells in the nose could outwit the flu virus, researchers said.
The study was published in the journal Science Immunology.

Disclaimer: No Business Standard Journalist was involved in creation of this content

You’ve reached your limit of 5 free articles this month.
Subscribe now for unlimited access.

Already subscribed? Log in

Subscribe to read the full story →
Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Access to Exclusive Premium Stories

  • Over 30 subscriber-only stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: Jun 05 2017 | 5:57 PM IST